Patient-reported outcomes for Hemophilia A patients treated with Mim8

Prof Cédric Hermans is the head of the haematology department at the Cliniques Universitaires St.-Luc in Brussels (Belgium). During ASH 2024 he presented the patient-reported outcomes for patients treated with Mim8 in the phase III FRONTIER2 study. In this study, Mim8 proved to be associated with a lower annualized bleeding rate (ABR) for treated bleeds compared to on-demand treatment and/or previous clotting factor concentrate (CFC) prophylaxis. In addition to this haemostatic efficacy, Mim8 prophylaxis also improved the physical functioning and reduced the treatment burden compared with on-demand treatment. Among patients who previously received CFC prophylaxis, physical functioning improved to a lesser extent. Joint pain intensity was not severe at baseline in all arms and did not change notably with Mim8 PPX. These findings demonstrate the holistic benefits of Mim8 beyond bleed protection and provide insights into opportunities for individualised care.